Department of Pharmacometrics and Pharmacokinetics, Meiji Pharmaceutical University

Assessing clinical outcomes of vancomycin treatment in adult patients with vancomycin-susceptible Enterococcus faecium bacteremia.
Antibiotics (Basel). 2023;12(11):1577.
Sasano H, Hanada K.

Physiologically based pharmacokinetic modeling of ponatinib to describe drug-drug interactions in patients with cancer.
Cancer Chemother Pharmacol. 2022 ;90(4):315-323.
Morita TO, Hanada K.

Pharmacokinetics and Adverse Effects of Clofazimine in the Treatment of Pulmonary Non-Tuberculous Mycobacterial Infection.
Antimicrob Agents Chemother. 2022 ;66(8):e0044122.
Watanabe F, Furuuchi K, Hanada K, Fujiwara K, Uesugi F, Hiramatsu M, Yoshiyama T, Shiraishi Y, Kurashima A, Ohta K, Morimoto K.

Genome-wide analysis identify novel germline genetic variations in ADCY1 influencing platinum-based chemotherapy response in non-small cell lung cancer.
Acta Pharm Sin B. 2022 ;12(3):1514-1522.
Mao C, Chen J, Zou T, Zhou Y, Liu J, Li X, Li X, Li M, Pan P, Zhuo W, Gao Y, Hu S, Xiao D, Wu L, Wang Z, Xu H, Yang W, Xu Y, Xiao H, Hanada K, Zhang W, Zhou H, Yin J, Liu Z.

Population Pharmacokinetic Model of Amiodarone and N-Desethylamiodarone Focusing on Glucocorticoid and Inflammation.
Biol Pharm Bull. 2022;45(7):948-954.
Hirai T, Kasai H, Takahashi M, Uchida S, Akai N, Hanada K, Itoh T, Iwamoto T.

Low-dosage ethambutol, less than 12.5 mg/kg/day, does not worsen the clinical outcomes of pulmonary Mycobacterium avium and Mycobacterium intracellulare disease: a retrospective cohort study.
Infection. 2022 ;50(4):879-887.
Watanabe F, Kaburaki S, Furuuchi K, Uesugi F, Fujiwara K, Tanaka Y, Yoshiyama T, Shiraishi Y, Kurashima A, Ohta K, Hanada K, Morimoto K.

A simultaneous quantitative LC/MS method for determination of five anti-Mycobacterium avium complex (MAC) disease drug in human plasma.
Jpn J Ther Drug Monit. 2022, 39(1):17-24.
Watanabe F, Morimoto K, Hanada K.

Involvement of the effect of renal hypoperfusion medications on vancomycin trough concentration: A secondary analysis using a retrospective observational data.
Basic Clin Pharmacol Toxicol.2021 ;129(5):376-384.
Hirai T, Hanada K, Iwamoto T, Itoh T

Effect of high-dose sulfamethoxazole/trimethoprim and glucocorticoid use on hyperkalemic event: A retrospective observational study.
J Infect Chemother. 2021 ;27(11):1607-1613.
Hirai T, Yamaga R, Ishikawa Y, Hanada K, Iwamoto T, Itoh T

Impact of concomitant medication on clinical outcomes in patients with advanced non‐small cell lung cancer treated with immune checkpoint inhibitors: A retrospective study.
Thoracic Cancer 2021 ;12(13):1983-1994.
Miura K, Sano Y, Niho S, Kawasumi K, Mochizuki N, Yoh K, Matsumoto S, Zenke Y, Ikeda T, Nosaki K, Kirita K, Udagawa H, Goto K, Kawasaki T, Hanada K

Population pharmacokinetic analysis and dose regimen optimization in Japanese infants with an extremely low birth weight.
Antimicrob Agents Chemother. 2021;65:e02523-20.
Sasano H, Aoki K, Arakawa R, Hanada K

Population pharmacokinetics and renal toxicity of cisplatin in cancer patients with renal dysfunction.
Cancer Chemother Pharmacol. 2020;86(4):559-566.
Morita OT, Sugita H, Minami H, Yamaguchi T, Hanada K

Effects of overweight and underweight on the treatment outcomes of rheumatoid arthritis patients treated with biological drugs: a retrospective observational descriptive study.
J Clin Pharm Ther. 2020;45(4):666-673.
Hirai T, Funaki A, Murakami K, Hanada K, Itoh T

Minocycline prevents and repairs the skin disorder associated with afatinib, one of the epidermal growth factor receptor-tyrosine kinase inhibitors for non-small cell lung cancer.
BMC Cancer 2020;20(1):279.
Sano K, Nakadate K, Hanada K

Renin-angiotensin system inhibitors for countering proteinuria inducedby angiogenesis inhibitors: a retrospective observational analysis.
Cancer Chemother Pharmacol. 2019;84(1):195-202.
Hirai T, Shuji Y, Takiyama M, Hanada K, Itoh T.

新薬開発時に行われる母集団薬物動態解析結果と臨床薬物動態試験解析結果の乖離
臨床薬理 2019; 50(3):89-95.
花田和彦、元村あゆみ、緒方宏泰

Impact of Q141K on the transport of epidermal growth factor receptor tyrosinekinase inhibitors by ABCG2.
Cells. 2019;8(7):763.
Inoue Y, Morita T, Onozuka M, Saito KI, Sano K, Hanada K, Kondo M, NakamuraY, Kishino T, Nakagawa H, Ikegami Y.

Risk factors for vancomycin nephrotoxicity and time course of renal function during vancomycin treatment.
Eur J Clin Pharmacol. 2019;75(6):859-866.
Hirai T, Hanada K, Kanno A, Akashi M, Itoh T.

抗がん剤のジェネリック医薬品の普及状況
臨床医薬　2018; 34(12):849-853.
杉本修治, 今井康人, 飯島肇, 菅野彩夏, 高橋みのり, 花田和彦